How do I subscribe to ongoing alerts?

Subscribe to /feed/company/chia-tai-tianqing-pharmaceutical-group-nanjing-shunxin-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. pipeline: 0 marketed, 0 filed, 8 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 8 Phase 3 2 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Gemcitabine hydrochloride for injection	Gemcitabine hydrochloride for injection	phase 3	Nucleoside analog; antimetabolite	Ribonucleotide reductase; DNA synthesis	Oncology
TQB2102 for injection	TQB2102 for injection	phase 3
Trastuzumab+ chemotherapy	Trastuzumab+ chemotherapy	phase 3	Monoclonal antibody + chemotherapy combination	HER2 (human epidermal growth factor receptor 2)	Oncology
Docetaxel combined + Trastuzumab +Pertuzumab	Docetaxel combined + Trastuzumab +Pertuzumab	phase 3	Chemotherapy + HER2-targeted monoclonal antibody combination	HER2 (trastuzumab and pertuzumab); microtubule stabilization (docetaxel)	Oncology
Tislelizumab+Oxaliplatin+Capecitabine	Tislelizumab+Oxaliplatin+Capecitabine	phase 3	PD-1 inhibitor + chemotherapy combination	PD-1 (programmed death receptor 1); DNA (oxaliplatin); thymidylate synthase (capecitabine)	Oncology
TQB2868 injection	TQB2868 injection	phase 3
TQB2930+ chemotherapy	TQB2930+ chemotherapy	phase 3	chemotherapy		Oncology
TQB2102 Injection	TQB2102 Injection	phase 3

Therapeutic area mix

Oncology · 5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
Shandong Provincial Hospital · 2 shared drug classes
Sun Yat-sen University · 2 shared drug classes
Celgene · 1 shared drug class
Centre Hospitalier Universitaire Dijon · 1 shared drug class
AstraZeneca · 1 shared drug class
Chengdu New Radiomedicine Technology Co. LTD. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/chia-tai-tianqing-pharmaceutical-group-nanjing-shunxin-pharmaceutical-co-ltd. Accessed 2026-05-16.